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ABSTRACT
Objectives Severe systemic inflammation associated 
with some stages of COVID-19 and in fatal cases led 
therapeutic agents developed or used frequently in 
Rheumatology being at the vanguard of experimental 
therapeutics strategies. The aim of this project was to 
elaborate EULAR Points to consider (PtCs) on COVID-19 
pathophysiology and immunomodulatory therapies.
Methods PtCs were developed in accordance 
with EULAR standard operating procedures for 
endorsed recommendations, led by an international 
multidisciplinary Task Force, including rheumatologists, 
translational immunologists, haematologists, 
paediatricians, patients and health professionals, based 
on a systemic literature review up to 15 December 2020. 
Overarching principles (OPs) and PtCs were formulated 
and consolidated by formal voting.
Results Two OPs and fourteen PtCs were developed. 
OPs highlight the heterogeneous clinical spectrum of 
SARS- CoV-2 infection and the need of a multifaceted 
approach to target the different pathophysiological 
mechanisms. PtCs 1–6 encompass the pathophysiology 
of SARS- CoV-2 including immune response, endothelial 
dysfunction and biomarkers. PtCs 7–14 focus on 
the management of SARS- CoV-2 infection with 
immunomodulators. There was evidence supporting 
the use of glucocorticoids, especially dexamethasone, 
in COVID-19 cases requiring oxygen therapy. No other 
immunomodulator demonstrated efficacy on mortality to 
date, with however inconsistent results for tocilizumab. 
Immunomodulatory therapy was not associated with 
higher infection rates.
Conclusions Multifactorial pathophysiological 
mechanisms, including immune abnormalities, play a 
key role in COVID-19. The efficacy of glucocorticoids 
in cases requiring oxygen therapy suggests that 
immunomodulatory treatment might be effective in 
COVID-19 subsets. Involvement of rheumatologists, 
as systemic inflammatory diseases experts, should 
continue in ongoing clinical trials delineating optimal 
immunomodulatory therapy utilisation in COVID-19.
INTRODUCTION
The rapid worldwide spread of the SARS- CoV-2 has 
led to an unpreceded pandemic. SARS- CoV-2 infec-
tion leads to heterogeneous disease phenotypes, 
from asymptomatic or mild disease associated with 
an uneventful recovery to severe disease leading to 
acute respiratory distress syndrome (ARDS), multi-
organ failure and death.1 Immune mechanisms are 
critically involved in evolution of severe COVID-
19, suggesting potential efficacy of immunomodu-
latory treatments.2 3
Key messages
What is already known about this subject?
 ► SARS- CoV-2 infection is potentially life 
threatening with severe disease being 
associated with immune system activation 
with severe pneumonia and pulmonary 
immunothrombosis that may be amenable to 
immunomodulatory treatments which have 
largely been pioneered in the rheumatology 
therapeutic arena.
 ► The enormous amount of studies published in a 
very short timeframe and the continuous flow 
of new data leads to difficulties in summarising 
best evidence for clinical practice for severe 
COVID-19 treatment.
What does this study add?
 ► Multifactorial pathophysiological mechanisms, 
including immune and non- immune cell 
abnormalities and loss of endothelial 
homeostasis, play a key role in  
COVID-19.
 ► These are first EULAR–endorsed ‘points to 
consider’ (PtC) providing a framework to 
optimise the use of immunomodulatory 
therapies for the care of people with SARS- 
CoV-2 infection.
 ► This article highlights areas of therapeutic 
success but also areas of uncertainty (eg, 
timing/add- in approach for glucocorticoids in 
combination with other immunomodulatory 
agents) that require to be addressed by further 
research and barriers to overcome in order to 
develop new therapeutic strategies for SARS- 
CoV-2 infection. 
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Since rheumatologists are at the vanguard of immunomodula-
tory therapy utilisation, they are well placed to provide insights 
in their usage, safety profile and timing towards potential miti-
gation of the severe inflammatory reactions associated with 
SARS- CoV-2 infection. Although an extremely large volume of 
publication is already available, most of the research is descrip-
tive and definitive randomised controlled trials (RCTs) remains 
scarce. In this rapidly evolving landscape, and with the need 
to optimally define therapeutics solutions, it is considerably 
important to provide the medical and scientific community with 
guidance using the best available evidence. This is especially the 
case since antiviral agents have thus far failed to show a signifi-
cant improvement of survival in COVID-19.4–6 The aim of this 
project was to elaborate EULAR points to consider (PtCs) on 
COVID-19 pathophysiology and immunomodulatory therapies 
from the rheumatology perspective through a systematic litera-
ture review (SLR)- based approach.
METHODS
After approval by the EULAR Executive Committee, the conve-
nors (XM and DGM) and the methodologist (PMM) led a multi-
disciplinary Task Force guided by the 2014 updated EULAR 
standardised operating procedures.7 The Task Force consisted of 
24 members from 8 different countries, including rheumatolo-
gists, translational immunologists (two of them also representing 
the Emerging EULAR Network), haematologists, paediatric rheu-
matologists, a methodologist, one health professional and one 
patient representative. Four virtual meetings of the Task Force 
were held, one inJuly 2020 and three in November 2020. Two 
fellows (AA and AN), guided by the methodologist, performed 
an SLR, retrieving individual studies on pathophysiology of 
SARS- CoV-2 infection and its management with immunomod-
ulatory therapies. Given the fast- paced publication of articles on 
treatment with potential impact on the formulation of PtCs, the 
last SLR update was performed on 11 December 2020. The SLR 
is published separately, however, it forms an integral part of the 
project.
Based on the presented evidence and expert opinion, and 
following a process of iterative discussion, the overarching prin-
ciples (OPs) and PtCs were developed. According to EULAR 
guidance, the steering group (convenors, methodologist and 
fellows) prepared draft- statements based on the evidence from 
the SLRs and each statement was presented, discussed and voted 
on (informal voting). The statements were accepted if more than 
75% of the Task Force approved the wording in the first round. 
If this was not reached, further discussion ensued and wording 
was refined. At least a 67% approval rate was required in the 
second voting round and more than 50% in the third round.8 
The level of evidence (LoE) supporting each statement was 
assigned according to the Oxford Centre for Evidence Based 
Medicine 2011 LoE.9 Finally, each Task Force member anony-
mously indicated their level of agreement with each PtC online 
(numerical rating scale ranging from 0=‘completely disagree’ to 
10=‘completely agree’). Based on the heterogeneity of studies 
gathered by the SLR and on the paucity of high- quality evidence 
(namely RCTs) despite the large amount of published articles, 
a research agenda was formulated. The final manuscript was 
reviewed and approved by all Task Force members, followed by 
ratification by the EULAR Executive Committee.
RESULTS
Two OP and 14 PtCs were formulated and encompass the patho-
physiology of SARS- CoV-2 infection and its treatment with 
immunomodulatory agents (table 1). The PtC are intended to 
provide insights in pathogenesis and guidance on therapeutic 
aspects, and the target users are healthcare providers taking care 
of patients infected with SARS- CoV-2 as well as patients and 
policy- makers.
Overarching principles
OP- A: the phenotype of SARS- CoV-2 infection is heterogeneous, 
ranging from asymptomatic to fatal disease due to multiorgan 
damage
The Task Force recognised the importance of outlining this 
concept as OP to set the scenario for the PtCs. A heterogeneous 
clinical spectrum is a hallmark of SARS- CoV-2 infection and a 
challenge for the clinicians. Patients with severe manifestations, 
severe systemic inflammation and ARDS remain difficult to treat 
leading to a negative outcome in a high number of cases.
OP- B: SARS- CoV-2 infection may need different treatment 
approaches, including antiviral, oxygen therapy, anti- coagulation 
and/or immunomodulatory treatment at different stages of the 
disease
An increasing number of articles outlined the complexity of 
SARS- CoV-2 pathophysiology and recommendations issued by 
the WHO and other key stakeholders10–12 reflect the necessity 
to combine supportive therapy along with agents with different 
mechanisms of action, for example, antiviral treatment, oxygen 
therapy, anticoagulation and the inflammatory response along 
with other key mechanism involved in the process. However, 
it is not yet clear when and how to combine these various 
approaches (eg, combination vs sequential therapy).
PtCs: pathophysiology of COVID-19
PtC-1: genetically determined differences including, but not 
limited to, immune gene pathways may contribute to the variable 
immune response to SARS- CoV-2 and ultimately impact on the 
disease prognosis (LoE 3/4)
Genetic differences may contribute to the clinical heteroge-
neity of SARS- CoV-2 infection with the type 1 interferon (IFN) 
pathway emerging as the strongest genetic association in both 
genome wide association studies (GWAS) and from Mendelian 
genetic studies of critically ill patients.13 A GWAS study also 
reported associations with immune response genes such as C- C 
Motif Chemokine Receptor 9 and C- X- C Motif Chemokine 
Receptor 6, and severe COVID-19.14 The same study reported 
higher risk of severe disease in people with blood group A.14 
Whole- exome sequencing reported variants of genes involved in 
IFN mediated immune response in a subset of patients with severe 
COVID-19 and patients showing these variants had hampered 
IFN immunity in vivo and in vitro.15–18 Data concerning (HLA) 
haplotypes are still conflicting.14 19 To note, low allelic vari-
ability of the ACE−2, whose binding by the SARS- CoV-2 spike 
protein facilitates cellular entry of the virus, was also observed 
Key messages
How might this impact on clinical practice?
 ► It is anticipated that clinicians will use these PtC as a basis 
for the optimal management of people with SARS- CoV-2 
infection and for further strategies for optimal therapy.
 ► These PtC will also support relevant stakeholders when 
evaluating new immunomodulatory therapeutic approaches 
to treat SARS- CoV-2 infection.
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in infected patients compared with normal subjects but was not 
associated with disease severity.20–22
PtC-2: cellular (LoE 3/4) and humoural (LoE 3) immune 
responses against SARS- CoV-2 vary across individuals, infection 
course and disease spectrum, but there is insufficient evidence to 
associate these directly with outcomes
The activation of phagocytes, antigen- sensitised T cells and 
B- cells have been extensively studied in SARS- CoV-2 infection. 
It is worth noting, however, that most studies assessed individual 
cell populations through extremely variable methods (ie, flow 
cytometry gating and sub- population definition) and measured 
specific anti- SARS- CoV-2 immunoglobulins with home- made 
assays using different viral proteins as substrate, thereby 
preventing definitive conclusions. Among the few studies using 
an unsupervised clustering approach through mass cytom-
etry and other high throughput sequencing techniques (single 
cell RNA sequencing, Cellular Indexing of Transcriptomes and 
Epitopes, Assay for Transposase- Accessible Chromatin, among 
others) several cell populations where reported to be consistently 
altered. The lymphoid compartment disruption was mostly char-
acterised by a reduction in CD4 and CD8 positive lymphocytes 
in patients with SARS- CoV-2 infection compared with healthy 
controls but also in patients displaying a severe disease vs milder 
phenotypes.23–32 In addition, this subset of patients displayed a 
higher amount of polyfunctional T cells along with an exhausted 
CD8+ phenotype as highlighted by a high PD-1+ expres-
sion.23 25 29 An alteration of cytotoxicity, as suggested by a reduc-
tion in granzymes A, B and perforin expression by CD8+ cells, 
was reported by one study.23 Natural killer and B- lymphocytes 
pools were also reduced in patients with SARS- CoV-2 infec-
tion when compared with healthy donors regardless of disease 
severity.25 27 In terms of myeloid response, an increase of clas-
sical CD14+ monocytes pool was consistently reported, along 
with a significant reduction of HLA- DR expression; as opposed 
to a reduction of dendritic cells in both mild and severe patients 
compared with healthy controls.23 26–28 33–36 In addition, the pool 
of immature neutrophils (pre and pro- neutrophils) was reported 
to be increased.35 36
With regard to the humoural response, a few studies used stan-
dardised, although based on different viral antigens, commer-
cially available ELISA or chemiluminescence immunoassays.37–41 
The authors reported appearance of anti- SARS- CoV-2 IgM 
within the first 2 weeks after the onset of symptoms but the fate 
of these antibodies is still controversial with studies reporting 
variable kinetics up to weeks 4–5 after the onset of symp-
toms. Conversely, anti- SARS- CoV-2 IgG variably appear either 
together with IgM in week 140 41 or in weeks 2-337 38 being still 
detectable up to week 4,38 week 637 40 or week 8.41 Data on the 
kinetics of neutralising antibodies are even more controversial. 
Additionally, results on other isotypes (IgA) are scarce, although 
potentially relevant for the clinical setting.
PtC-3: levels of many proinflammatory cytokines, especially 
serum interleukin-6, are elevated in COVID-19 and could be 
associated with outcome (LoE 3/4)
The cytokine expression profile during the course of 
SARS- CoV-2 infection has already been extensively studied. Since 
the level of proinflammatory cytokines is elevated in some stages 
of the disease, but not at very high levels, the group considered 
Table 1 Overarching principles and points to consider on COVID-19 pathophysiology and immunomodulatory treatment from the rheumatology 
perspective, with levels of evidence (LoE) and levels of agreement (LoA)
Overarching principles
LoA mean (SD);
% of votes ≥8/10
A. The phenotype of SARS- CoV-2 infection is heterogeneous ranging from asymptomatic to lethal disease due to multiorgan damage. 9.92 (0.3); 100
B. SARS- CoV-2 infection may need different treatment approaches, including antiviral, oxygen therapy, anticoagulation and/or immunomodulatory treatment 
at different stages of the disease.
9.92 (0.3); 100
Points to consider   
COVID-19 pathophysiology   
1. Genetically determined differences including, but not limited to, immune gene pathways may contribute to the variable immune response to SARS- CoV-2 
and ultimately impact on the disease prognosis (LoE 3/4).
9.25 (1.2); 100
2. Cellular (LoE 3/4) and humoral (LoE 3) immune responses against SARS- CoV-2 vary across individuals, infection course and disease spectrum, but there is 
insufficient evidence to associate these directly with outcomes.
8.71 (1.1); 83
3. Levels of many proinflammatory cytokines, especially serum IL-6, are elevated in COVID-19 and could be associated with outcome (LoE 3/4). 8.79 (1.0): 96
4 .Hyperactivation of platelets, the complement system, endothelial damage and loss of endothelial homeostasis are pathophysiological mechanisms 
facilitating hypercoagulability and thrombosis during SARS- CoV-2 infection (LoE 4).
9.0 (1.1); 92
5. Multiparameter algorithms including neutrophil- to- lymphocyte ratio and acute phase reactants (eg, C reactive protein, ferritin) may be helpful to predict 
survival, mortality or disease progression and severity (LoE 4).
8.88 (1.3); 88
6. Primary infection with SARS- CoV-2 in children is largely a benign event. However, a small number of children develop a multisystem inflammatory 
syndrome which may reflect distinct pathophysiological mechanisms compared with adults (LoE 4/5).
9.38 (0.9); 96
Immunomodulatory therapy   
7. In non- hospitalised patients with SARS- CoV-2 infection there is currently no evidence to support the initiation of immunomodulatory therapy (LoE 2/3/4). 9.58 (1.0); 96
8. In hospitalised patients with SARS- CoV-2 infection that do not need oxygen therapy there is currently no evidence to support the initiation of 
immunomodulatory therapy to treat their COVID-19 (LoE 2/3/4).
9.04 (1.6); 88
9. Hydroxychloroquine should be avoided for treating any stage of SARS- CoV-2 infection since it does not provide any additional benefit to the standard of 
care, and could worsen the prognosis in more severe patients particularly if co- prescribed with azithromycin (LoE 2).
9.75 (0.5); 100
10. In patients with COVID-19 requiring supplemental oxygen, non- invasive or mechanical ventilation, systemic glucocorticoids should be used since they 
can decrease mortality; most evidence concerns the use of dexamethasone (LoE 2/3).
9.67 (0.7); 100
11. An evolving RCT landscape cannot yet allow formal recommendation of the routine use of tocilizumab in patients with COVID-19 requiring oxygen 
therapy, non- invasive or invasive ventilation (LoE 2).
8.79 (1.2): 83
12. In COVID-19 there is no robust evidence to support the use of anakinra at any disease stage (LoE 2/4). 9.38 (1.0); 96
13. In patients with COVID-19 requiring non- invasive ventilation or high- flow oxygen, the combination of remdesivir plus baricitinib could be considered 
since it can decrease time to recovery and accelerate improvement in clinical status (LoE 2).
8.19 (2.2); 88
14. In COVID-19 there is currently insufficient evidence to recommend the use of other immunomodulators, including ruxolitinib, IVIg, convalescent plasma 
therapy except in Ig- deficient patients, interferon kappa, interferon beta, leflunomide, colchicine (LoE 2), sarilumab, lenzilumab, eculizumab, cyclosporine, 
interferon alpha (LoE 3), canakinumab (LoE 4).
9.42 (0.9); 96
IL-6, interleukin 6; IVIg, intravenous Ig; RCT, randomised controlled trial.
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that the term severe systemic inflammatory state seems more 
appropriate than the frequently used ‘cytokine storm’.42 Of 
interest, while most studies used a targeted approach towards 
one cytokine or one family of cytokines subsequently leading to 
bias, only a few used multiparametric assays allowing the multi-
variable assessment of the expression of several cytokines at the 
same time. Among these, several studies reported a consistent 
elevation of interleukin (IL)-6, IL-1 beta and tumor necrosis 
factor along with Th1 associated cytokines (IFN- gamma, IL-18) 
in COVID-19 patients compared with healthy donors but 
the magnitude of cytokine elevations was greater in patients 
displaying more severe disease phenotypes compared with mild 
or moderate diseases.28 33 43–45
These results are concordant with the large amount of 
studies correlating IL-6 levels with disease severity and negative 
outcomes.46 In addition to these, anti- inflammatory cytokines 
and a broad range of chemokines and growth factors expression 
profiles were inconsistently reported to be disrupted to a vari-
able extent according to disease severity and outcomes but these 
results were not felt consistent enough by the TF to lead to the 
formulation of a PtC.47 However, the extent of cytokinaemia 
in cases of severe and critical COVID-19 is less than that seen 
in other disorders associated with elevated cytokine production, 
such as chimeric antigen receptor T- cell- induced cytokine release 
syndrome and non- COVID-19 ARDS.42 48
PtC-4: hyperactivation of platelets, the complement system, 
endothelial damage and loss of endothelial homeostasis are 
pathophysiological mechanisms facilitating hypercoagulability 
and thrombosis during SARS- CoV-2 infection (LoE 4)
A large number of studies described an increased prevalence 
of thrombosis and thromboembolic disease in patients with 
SARS- CoV-2 infection.49 Controversy still exists as to whether 
hypercoagulability in SARS- CoV-2 infection may be immune 
driven or immunothrombotic in nature or may be linked to 
direct viral endothelitis (or both). Platelet aggregation and acti-
vation, as expected in the context of endothelial injury and 
immune activation were observed and were more pronounced in 
severe COVID-19.50–60
PtC-5: multiparameter algorithms including neutrophil- 
to- lymphocyte ratio and acute phase reactants (eg, C reactive 
protein, ferritin) may be helpful to predict survival, mortality or 
disease progression and severity (LoE 4)
In order to help clinicians in disease management, several 
studies aiming at creating algorithms for prediction of disease 
progression, severity or outcomes have been published.61–73 
Among them, a few have used robust statistical approaches using 
uni- and multivariate analysis, followed by logistic regression or 
least absolute shrinkage and selection operator. Most of them 
included various parameters from clinical data (demographics, 
comorbidities, symptoms), biological results (acute phase 
reactants such as C reactive protein, ferritin, procalcitonin, 
calprotectin; coagulation markers such as platelets, D- dimer, 
prothrombin time; immune cell count such as neutrophils, 
lymphocytes or neutrophil- to- lymphocyte ratio) or imaging 
results (chest CT).
The relevance of combining different parameters for prog-
nostic purposes in further underscored by the recent release of 
predictive criteria for COVID-19 severe systemic inflammatory 
state.74
PtC-6: primary infection with SARS- CoV-2 in children is 
largely a benign event. However, a small number of children 
develop a multisystem inflammatory syndrome which may 
reflect distinct pathophysiological mechanisms compared with 
adults (LoE 4/5)
Epidemiological data pertaining to SARS- CoV-2 infec-
tion in children are rather homogeneous describing mild to 
moderate symptoms in most cases.75 However, from the end 
of April 2020, a number of alerts have been raised in several 
countries about children with proven SARS- CoV-2 infection 
developing a multisystem inflammatory syndrome (MIS- C).76 
More recently reports of MIS- C in young adults have been 
published.77 Studies comparing clinical and serological features 
of children and adults with SARS- CoV-2 infection are scarce 
and included small cohorts of patients hence they do not allow 
to draw definitive conclusions on similarities and differences 
of SARS- CoV-2 infection across the lifespan.78 However, the 
discussion on this PtC was led by the paediatric rheumatolo-
gists and resulted in an agreement to include expert opinion 
given the paucity of data from the SLR. In particular, the Task 
Force supported the hypothesis that this clinical heteroge-
neity may reflect distinct pathophysiological mechanisms, not 
yet fully elucidated, that occur in children and in adults with 
SARS- CoV-2 infection.
PtCs: immunomodulatory treatment
PtC-7: in non- hospitalised patients with SARS- CoV-2 infection 
there is currently no evidence to support the initiation of immu-
nomodulatory therapy (LoE 2/3/4)
The literature assessing the efficacy of immunomodula-
tory therapies on reducing time to an undetectable viral load, 
reducing the duration of clinical symptoms or preventing clin-
ical deterioration in patients presenting with mild or moderate 
forms including mild hypoxaemia not requiring hospitalisation 
remains scarce since most of the clinical research has included 
more severe patients. However, it is worth noting that among 
the few studies available, none provided evidence of treatment 
efficacy in this specific population. More specifically, none of 
the RCTs assessing the efficacy of hydroxychloroquine (HCQ) 
in non- hospitalised patients reported positive outcomes.79 80 It is 
possible that this phase of SARS- CoV-2 infection requires more 
efficient anti- viral drugs than immunomodulatory drugs.
PtC-8: In hospitalised patients with SARS- CoV-2 infection 
that do not need oxygen therapy there is currently no evidence to 
support the initiation of immunomodulatory therapy (LoE 2/3/4)
A large number of studies on hospitalised patients with 
SARS- CoV-2 infection and various disease severity investigated 
immunomodulatory therapy. However, none of the investigated 
compounds except leflunomide in one small RCT,81 specifi-
cally demonstrated to be effective if added to standard of care 
(SOC) in hospitalised patients with mild- to- moderate disease 
not requiring oxygen therapy compared with SOC only. Of 
note, in the large RECOVERY RCT, analysis of the subgroup of 
patients without oxygen support showed a possible (not statisti-
cally significant) deleterious effect of dexamethasone (DEX) on 
mortality: OR 1.22, 95% CI 0.93 to 1.61, p=0.14.82 Likewise, 
HCQ was clearly ineffective in three RCTs including patients 
with mild to moderate disease and it even showed a negative 
safety profile.79 80 Due to the lack of efficacy and the safety 
concerns also in patients with severe COVID-19, and the histor-
ical debate about the role of HCQ in SARS- CoV-2 infection, 
with HCQ shortages being reported during the SARS- CoV-2 
pandemic, the group decided to elaborate a separate PtC for this 
drug.
PtC-9: HCQ should be avoided for treating any stage of 
SARS- CoV-2 infection since it does not provide any additional 
benefit to the SOC, and could worsen the prognosis in more severe 
patients particularly if coprescribed with azithromycin (LoE 2)
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In the early phases of the SARS- CoV-2 pandemic, HCQ was 
extensively used for the management of infected patients due to 
its known antiviral and immunomodulatory effects.83 However, 
the initial promising data from prospective/retrospective studies 
have not been confirmed by RCTs. Data from eight RCTs on 
HCQ in patients with SARS- CoV-2 infection and different 
degrees of COVID-19 severity consistently showed that the 
addition of this compound to SOC did not provide any benefit 
at any stage of the disease.79 80 84–89 Importantly, the RECOVERY 
study reported that for some outcomes such as progression to 
invasive mechanical ventilation (IMV) or death, and proba-
bility to be discharged alive, the addition of HCQ to SOC led to 
even worse outcomes compared with SOC alone. Furthermore, 
safety concerns have been raised since patients treated with 
HCC+SOC displayed a higher rate of adverse events compared 
with SOC only at any disease stage, mainly if associated with 
azithromycin. For example, HCQ- treated patients with severe 
COVID-19 displayed prolongation of the corrected QT interval, 
elevation of liver- enzymes and higher risk of death from non–
SARS- CoV-2 cardiac causes.86 87
PtC-10: in patients with COVID-19 requiring supplemental 
oxygen, non- IMV, systemic glucocorticoids should be used since 
they can decrease mortality; most evidence concerns the use of 
DEX (LoE 2/3)
This PtC was elaborated based on the results of 6 RCTs on 
patients with severe COVID-19. Two trials investigated DEX,82 90 
two investigated methylprednisolone (MTP),91 92 and two inves-
tigated hydrocortisone.93 94 While the overall analysis of patients 
yielded conflicting results for the majority of outcomes, the 
evidence on mortality from subgroup analysis was striking 
and revealed the beneficial effect of DEX and MTP in specific 
subgroups of patients. The RECOVERY trial demonstrated that 
the addition of DEX to SOC reduced mortality only in patients 
requiring respiratory support.82 The addition of MTP to SOC 
reduced mortality only in patients aged 60 or over by mecha-
nisms potentially including rescue of immunosenescence.91 The 
group agreed that the evidence was more consistent for DEX 
rather than for MTP. Based on this data, DEX has been included 
in most of the recommendations of treatment for critical inten-
sive care unit (ICU) patients and for mild- to- moderate pneu-
monia needing oxygen in medical wards. Of note, in the latter 
population, there is no study to decipher the effect of gluco-
corticoids between the patients requiring a low rate of oxygen 
1–2 L/min) and those requiring higher rate (3–15 L/min). It is an 
important point since the pathophysiology might be different in 
both groups.
PtC-11: an evolving RCT landscape cannot yet allow formal 
recommendation of the routine use of tocilizumab in patients 
with COVID-19 requiring oxygen therapy, non- invasive or inva-
sive ventilation (LoE 2)
The SLR retrieved 104 articles evaluating tocilizumab (TCZ) 
in SARS- CoV-2 infection and only three were RCTs.95–97 A 
scenario similar to that reported above for HCQ occurred for 
TCZ. Based on the evidence of the severe systemic inflamma-
tion at some stages of the disease, where IL-6 is perceived to 
be ‘a leading actor’ and on results from early studies with low 
LoE, many of which lacking a control group, prompted initial 
widespread TCZ use. Two published RCT96 97 were negative but 
probably included mild patients, some of them not requiring 
oxygen support since day-28 mortality was low: 4.9% and 2.4%, 
respectively. The third published study (CORIMUNO-19)95 
focusing on patients requiring at least 3 L/min oxygen but not in 
ICU showed a 33% reduction of non- invasive or invasive venti-
lation (NIV) or death at day 14, but day-28 mortality was not 
different between groups (around 12%). Of note, two studies 
in the preprint phase, the first one (EMPACTA) with the same 
inclusion criteria as CORIMUNO-19), and positive with the 
same composite primary outcome, the second one (COVACTA) 
negative for its primary outcome, but with positive results in the 
post hoc analysis of patients not in ICU. Lastly, in the patients 
recently admitted in ICU within 2 days, the REMAP- CAP study 
was prematurely stopped because of positive results on survival 
with TCZ98 and an emulated trial in the same population found 
an improvement of survival.99 Interestingly, safety of TCZ was 
good in all these studies with in some of them a decrease of 
the rate of serious infections in the TCZ arm versus placebo or 
usual care arm. To summarise, despite the encouraging signals 
in some subgroups, it remains impossible at the date of this 
paper to draw definitive conclusions and to formulate a PtC 
either recommending or discouraging the use of TCZ in severe 
COVID-19. Meta- analysis on aggregated or individual patient 
data and further clinical trials are warranted and results from 
these trials will inform about the potential benefit of TCZ, in 
selected patients. Observational studies suggested benefit of 
glucocorticoids in combination with TCZ, but RCTs are needed 
for the evaluation of TCZ in addition to DEX/MTP vs DEX/
MTP alone. This will be an important step for determining the 
possible place of this drug as an ‘add on therapy’ in glucocorti-
coid non- responsive cases.
PtC-12: in COVID-19 there is no robust evidence to support 
the use of anakinra at any disease stage (LoE 2/4)
At present, the only RCT available on anakinra in SARS- CoV-2 
infection was conducted by the CORIMUNO-19 Collaborative 
group in mild- to- moderate COVID-19 pneumonia requiring at 
least 3 L/min oxygen but not receiving NIMV or IMV ventilation 
at randomisation. The study was stopped early following the 
recommendation of the data and safety monitoring committee 
since no beneficial effect was observed.100 As far as moderate- 
to- severe COVID-19 is concerned, conflicting results have been 
reported from three retrospective controlled studies.101–103
PtC-13: in patients with COVID-19 requiring NIV or high- flow 
oxygen, the combination of remdesivir plus baricitinib could be 
considered since it can decrease time to recovery and accelerate 
improvement in clinical status (LoE 2)
At present, the only RCT available on baricitinib in SARS- CoV-2 
infection compared remdesevir + baricitinib versus remdesevir 
+placebo.104 Patients receiving baricitinib had a median time to 
recovery of 7 days, as compared with 8 days with control (rate 
ratio for recovery, 1.16; 95% CI 1.01 to 1.32; p=0.03), except 
in the subgroup of patients with a baseline NIV (including high 
flow oxygen) in whom median time to recovery was 10 days 
with the combination, as compared with 18 days with control 
(rate ratio for recovery, 1.51; 95% CI 1.10 to 2.08). In light 
of these data, the main issue that emerged during the discus-
sion pertained to the target population in which to recommend 
baricitinib + remdesivir. The majority of Task Force members 
agreed to suggest baricitinib + remdesivir only in the subgroup 
of patients with a baseline NIV since the small difference in time 
to recovery observed in the overall cohort was felt clinically not 
pertinent, although statistically significant.
PtC-14: in COVID-19 there is currently insufficient evidence 
to recommend the use of other immunomodulators, including 
ruxolitinib, IVIg, convalescent plasma therapy except in Ig- de-
ficient patients, IFN kappa, IFN beta, leflunomide, colchicine 
(LoE 2), sarilumab, lenzilumab, eculizumab, cyclosporine, IFN 
alpha (LoE 3), canakinumab (LoE 4)
Various other immunomodulatory compounds have been 
investigated in SARS- CoV-2 infection. However, the available 
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evidence to date is either too scarce/conflicting, although from 
RCTs, as in the case of ruxolitinib, IFN beta, IFN kappa, IVIg 
and convalescent plasma or with too low LoE/conflicting results 
as in the case of sarilumab, lenzilumab, eculizumab, IFN alpha, 
tumour necrosis factor alpha inhibitors and canakinumab (LoE 
3/4). Hence, no recommendation either in favour or against 
the use of these compounds in SARS- CoV-2 infection could be 
formulated. The group did not comment on drugs for which 
published literature was not available, although being in the 
pipeline.
DISCUSSION
These are the first EULAR- endorsed PtCs on pathophysiology 
and immunomodulatory therapy of SARS- CoV-2 infection. 
Their aim is to serve as a reference for clinicians involved in 
the care of people with SARS- CoV-2 infection and the use of 
immunomodulatory therapy as seen from the translational rheu-
matology perspective. They have been proposed by a rheuma-
tology/multidisciplinary team. Since rheumatologists are the 
experts on inflammatory systemic diseases and on the use of 
immunomodulatory therapy, they should be involved in mecha-
nistic/pathophysiological studies and in the design, conduct and 
interpretation of trials with immunomodulatory therapies in 
COVID-19.
With the OPs, we recognised that the management of 
SARS- CoV-2 infection, with its heterogeneous nature, 
requires a multifaceted approach considering viral replica-
tion, hypercoagulability and the inflammatory response, the 
latter of which was our specific focus. In this regard, these 
PtCs focus on pathophysiology and immunomodulatory 
treatment and the discussion leading to formulation of these 
PtCs was based not only on the evidence obtained by the 
SLR but also on the opinion of experts of inflammation and 
immunomodulatory therapy.
These PtCs in no way attempt to undermine local regula-
tions or guidelines released by overarching institutions such 
as the WHO. Rather, they seek to provide recommendations 
of good practice integrating evidence- based medicine and 
expert opinion, which can help clinicians analysing their 
own therapeutic strategy and inspire changes where appro-
priate. It is important to emphasise that our findings do 
not apply to people living with rheumatic and musculoskel-
etal diseases (RMDs) receiving immunomodulatory treat-
ments where a dedicated EULAR Task Force has already 
developed provisional recommendations for the manage-
ment of people with RMDs in the context of SARS- CoV-2 
pandemic.105
One major pitfall encountered in the development of these 
PtCs was the extremely large bulk of literature that challenged 
its appraisal including a surprisingly high number of articles 
lacking original data, thus being uninformative to the discus-
sion. Interestingly, the narrative around ‘cytokine storm’ and 
its specific therapy at the start of pandemic lacked evidence so 
was not included in the OP or PTC in the present recommen-
dations. The rapidly evolving COVID-19 landscape along with 
the ongoing release of new studies represents a major challenge, 
since recommendations should only be elaborated on existing 
published peer- reviewed literature and following robust meth-
odological procedures. To overcome these issues, we performed 
hand- search work throughout the entire SLR process and 
TF meetings, and based these PtCs on a very recent literature 
update. Based on the SLR results and the inputs from the group, 
a research agenda was also outlined (box 1).
In conclusion, these EULAR PtCs provide relevant guid-
ance on the pathophysiology of SARS- COV-2 infection, 
especially immunomodulatory therapy utilisation from the 
rheumatology perspective. Indeed, the pathophysiology with 
an initial viral alveolitis and subsequent immunothrombosis 
and available evidence points towards a central role for 
immunomodulatory therapy, especially glucocorticoids, in 
improving disease survival in severe COVID-19. These first 
EULAR PtCs are intended to evolve and should be updated 
in response to the rapid increase of knowledge about the 
disease and the forthcoming vaccines.
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